서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 14 of 14

Issue DateTitle / Author(s) / CitationFileAltmetrics
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2006-04
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
DOI
2010-10
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
DOI
2013-07
Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib
DOI
2013-09
How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
view fileDOI
2013-10
A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype
DOI
2014-08
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

Keam, Bhumsuk; Kim, Dong-Wan; Park, Jin Hyun; Lee, Jeong-Ok; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

International Journal of Clinical Oncology, Vol.19 No.4, pp.594-600

DOI
2014-10
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
DOI
2014-12
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
DOI
2016-03
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
DOI
2017-04
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
DOI
2017-05
Molecular Testing of Lung Cancers
DOI
2017-07
Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression

Koo, Taeyoung; Yoon, A-Rum; Cho, Hee-Yeon; Bae, Sangsu; Yun, Chae-Ok; Kim, Jin-Soo

Nucleic Acids Research, Vol.45 No.13, pp.7897-7908

view fileDOI
2019-07
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer
view fileDOI
1